Pulmatrix company info

What does Pulmatrix do?
Pulmatrix (NASDAQ:PULM) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of pulmonary diseases. With a keen interest in leveraging its proprietary technology platform, Pulmatrix aims to improve the lives of patients suffering from serious pulmonary conditions including chronic obstructive pulmonary disease (COPD), asthma, and infectious diseases by developing inhaled therapies that lead to better efficacy, safety, and convenience. One of the company's flagship projects involves a novel formulation designed to effectively deliver medications directly to the lungs, promising a significant advancement in the treatment of pulmonary diseases. Pulmatrix is motivated by its mission to address the unmet medical needs within the respiratory health sector, pushing the boundaries of pulmonary medicine through cutting-edge research and development.
Pulmatrix company media
Company Snapshot

Is Pulmatrix a public or private company?


How many people does Pulmatrix employ?


What sector is Pulmatrix in?

pie chart
Health Care

Where is the head office for Pulmatrix?

location pin
Head Office
Bedford, United States

What year was Pulmatrix founded?

founded flag
Year Founded
What does Pulmatrix specialise in?
/Respiratory Therapies /Inhalation Drugs /Pulmonary Delivery /Nanoparticle Technology /Bronchiectasis Treatment /COPD Medications

What are the products and/or services of Pulmatrix?

Overview of Pulmatrix offerings
PUR1900, an inhaled antifungal medication aimed at treating allergic bronchopulmonary aspergillosis in asthma patients.
PUR3100, a fast-acting, inhalable migraine therapy designed for rapid relief.
iSPERSE technology, a proprietary dry powder platform for delivering small molecule drugs directly to the lungs.
PUR5700, a novel inhaled formulation targeting the treatment of idiopathic pulmonary fibrosis, aiming to reduce fibrosis progression.

Who is in the executive team of Pulmatrix?

Pulmatrix leadership team
  • Mr. Teofilo David Raad MBA
    Mr. Teofilo David Raad MBA
    President, CEO & Director
  • Mr. Peter  Ludlum CMA, MBA
    Mr. Peter Ludlum CMA, MBA
    Interim CFO and Principal Accounting & Financial Officer
  • Dr. Alexander M. Klibanov Ph.D.
    Dr. Alexander M. Klibanov Ph.D.